A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Study of Drug in Patients with Advanced Solid Malignancies and Lymphoma
Sponsor: Rgenix, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR3867
U.S. Govt. ID: NCT02922764
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study has two parts. Participants will be enrolled in the second part of the study. The names of the study drugs are RGX-104, nivolumab, ipilimumab, docetaxel, carboplatin, and pemetrexed. The purpose of the first part of the study is to determine the highest dose of RGX-104 the body can handle. The purpose of the second part is to determine if the highest dose of RGX-104 determined in the first part might be an effective treatment option for people with advanced cancers. Both parts of the study will try to understand the safety and side effects of RGX-104.
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a confirmed solid tumor that continues to grow? (Example: ovarian, breast, lung, or skin cancer) Yes No
Have you had treatment for your disease in the past? Or, does a standard therapy not exist for your disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator